MX2020013865A - Tratamiento genico combinatorio. - Google Patents
Tratamiento genico combinatorio.Info
- Publication number
- MX2020013865A MX2020013865A MX2020013865A MX2020013865A MX2020013865A MX 2020013865 A MX2020013865 A MX 2020013865A MX 2020013865 A MX2020013865 A MX 2020013865A MX 2020013865 A MX2020013865 A MX 2020013865A MX 2020013865 A MX2020013865 A MX 2020013865A
- Authority
- MX
- Mexico
- Prior art keywords
- gene therapy
- combinatorial gene
- relates
- present
- combination therapy
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001476 gene delivery Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Manufacturing & Machinery (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810301.0A GB201810301D0 (en) | 2018-06-22 | 2018-06-22 | Combinatorial gene therapy |
| PCT/EP2019/066471 WO2019243574A1 (en) | 2018-06-22 | 2019-06-21 | Combinatorial gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013865A true MX2020013865A (es) | 2021-03-25 |
Family
ID=63042788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013865A MX2020013865A (es) | 2018-06-22 | 2019-06-21 | Tratamiento genico combinatorio. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210252164A1 (https=) |
| EP (1) | EP3810206B1 (https=) |
| JP (1) | JP2021528407A (https=) |
| KR (1) | KR20210024040A (https=) |
| CN (1) | CN112955185A (https=) |
| AU (1) | AU2019289998A1 (https=) |
| BR (1) | BR112020026260A2 (https=) |
| CA (1) | CA3104432A1 (https=) |
| GB (1) | GB201810301D0 (https=) |
| IL (1) | IL279584A (https=) |
| MX (1) | MX2020013865A (https=) |
| SG (1) | SG11202012727SA (https=) |
| WO (1) | WO2019243574A1 (https=) |
| ZA (1) | ZA202100244B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3226019A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
| CN121038801A (zh) | 2022-10-24 | 2025-11-28 | Ags治疗简易股份公司 | 来自微藻的细胞外囊泡、它们在鼻内施用时的生物分布及其用途 |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001273150A1 (en) * | 2000-07-20 | 2002-02-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| CN102813942A (zh) * | 2012-08-15 | 2012-12-12 | 钟志容 | 脂质超声微泡介导的腺相关病毒基因转染制剂及制备工艺 |
| WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| EP3495486B1 (en) * | 2013-12-30 | 2020-12-16 | CureVac AG | Artificial nucleic acid molecules |
| WO2016033695A1 (en) * | 2014-09-05 | 2016-03-10 | Exerkine Corporation | Exosome isolation |
| CA2962081A1 (en) * | 2014-09-26 | 2016-03-31 | Exerkine Corporation | Exosomes useful to treat lysosomal storage disease |
| AU2017241534A1 (en) * | 2016-03-28 | 2018-10-04 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitability |
| GB2568255A (en) * | 2017-11-08 | 2019-05-15 | Evox Therapeutics Ltd | Exosomes comprising RNA therapeutics |
-
2018
- 2018-06-22 GB GBGB1810301.0A patent/GB201810301D0/en not_active Ceased
-
2019
- 2019-06-21 CA CA3104432A patent/CA3104432A1/en active Pending
- 2019-06-21 KR KR1020217001827A patent/KR20210024040A/ko not_active Withdrawn
- 2019-06-21 SG SG11202012727SA patent/SG11202012727SA/en unknown
- 2019-06-21 EP EP19732641.6A patent/EP3810206B1/en active Active
- 2019-06-21 AU AU2019289998A patent/AU2019289998A1/en not_active Abandoned
- 2019-06-21 JP JP2020570467A patent/JP2021528407A/ja active Pending
- 2019-06-21 CN CN201980042058.3A patent/CN112955185A/zh active Pending
- 2019-06-21 US US17/252,335 patent/US20210252164A1/en not_active Abandoned
- 2019-06-21 MX MX2020013865A patent/MX2020013865A/es unknown
- 2019-06-21 WO PCT/EP2019/066471 patent/WO2019243574A1/en not_active Ceased
- 2019-06-21 BR BR112020026260-9A patent/BR112020026260A2/pt not_active IP Right Cessation
-
2020
- 2020-12-20 IL IL279584A patent/IL279584A/en unknown
-
2021
- 2021-01-13 ZA ZA2021/00244A patent/ZA202100244B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3104432A1 (en) | 2019-12-26 |
| EP3810206B1 (en) | 2024-01-24 |
| CN112955185A (zh) | 2021-06-11 |
| EP3810206A1 (en) | 2021-04-28 |
| BR112020026260A2 (pt) | 2021-03-23 |
| US20210252164A1 (en) | 2021-08-19 |
| GB201810301D0 (en) | 2018-08-08 |
| JP2021528407A (ja) | 2021-10-21 |
| SG11202012727SA (en) | 2021-01-28 |
| AU2019289998A1 (en) | 2021-02-04 |
| KR20210024040A (ko) | 2021-03-04 |
| WO2019243574A1 (en) | 2019-12-26 |
| IL279584A (en) | 2021-03-01 |
| ZA202100244B (en) | 2022-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013865A (es) | Tratamiento genico combinatorio. | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| PH12019501959A1 (en) | Therapeutic rna | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| EP4378536A3 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| MX2019006296A (es) | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. | |
| MX2022003859A (es) | Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| PH12016500862A1 (en) | Autotaxin inhibitor compounds | |
| MX2014002393A (es) | Inhibidores de rock suaves, novedosos. | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EP3995581A3 (en) | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| JOP20180094A1 (ar) | مركب حلقي غير متجانس كمثبط بروتين كيناز | |
| MX2020003961A (es) | Uso de inhibidores de p38 para reducir la expresion de dux4. | |
| EP4345165A3 (en) | Gene therapy for retinitis pigmentosa | |
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения |